Poor prognosis osteosarcoma: new therapeutic approach

被引：33

作者：

Fagioli, F.

Biasin, E.

Mereuta, O. M.

Muraro, M.

Luksch, R. ^{[1
]}

Ferrari, S. ^{[2
]}

Aglietta, M. ^{[3
]}

Madon, E.

机构：

[1] Ist Nazl Studio & Cura Tumori, Dept Pediat Oncol, I-20133 Milan, Italy

[2] Univ Bologna, Ist Ortoped Rizzoli, Div Chemotherapy, Bologna, Italy

[3] Univ Turin, IRCC, Turin, Italy

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 41卷 / Suppl 2期

关键词：

high-grade osteosarcoma; high-dose chemotherapy; immunotherapy; cytotoxic lymphocytes;

D O I：

10.1038/bmt.2008.71

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Over the past 30 years, a significant improvement in the prognosis of localized osteosarcoma of the extremities has been observed. Despite these results, approximately 30-40% of patients will relapse, mostly within the first 3 years from diagnosis. The prognosis of patients with recurrent disease or metastases at diagnosis is poor. To improve the survival in this patient population, several attempts have been made. An increased dose intensity of chemotherapy induces short lasting remission but does not increase the survival. In the era of targeted therapy, few drugs have been tested with dismal results. The use of biological agents endowed with immunomodulant activity (that is IL-2) or reduced-intensity allogeneic hemopoietic SCT has produced intriguing results that need further confirmation. In this context, an ongoing study explores the antitumor activity of specific T-cytotoxic lymphocytes.

引用

页码：S131 / S134

页数：4

共 31 条

[1] High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases [J].

Anderson, PM ;

Wiseman, GA ;

Dispenzieri, A ;

Arndt, CAS ;

Hartmann, LC ;

Smithson, WA ;

Mullan, BP ;

Bruland, OS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :189-196

[2] Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].

Bacci, G ;

Ferrari, S ;

Bertoni, F ;

Ruggieri, P ;

Picci, P ;

Longhi, A ;

Casadei, R ;

Fabbri, N ;

Forni, C ;

Versari, M ;

Campanacci, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027

[3] High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian sarcoma group/Scandinavian sarcoma group pilot study [J].

Bacci, G ;

Ferrari, S ;

Longhi, A ;

Picci, P ;

Mercuri, M ;

Alvegard, TA ;

Saeter, G ;

Donati, D ;

Manfrini, M ;

Lari, S ;

Briccoli, A ;

Forni, C .

JOURNAL OF CHEMOTHERAPY, 2002, 14 (02) :198-206

[4] Neoadjuvant therapy for localized extremity osteosarcoma.: Experience of the Cooperative Osteosarcoma Study Group COSS with 925 patients [J].

Bielack, S ;

Kempf-Bielack, B ;

Schwenzer, D ;

Birkfellner, T ;

Delling, G ;

Ewerbeck, V ;

Exner, GU ;

Fuchs, N ;

Göbel, U ;

Graf, N ;

Heise, U ;

Helmke, K ;

von Hochstetter, AR ;

Jürgens, H ;

Maas, R ;

Münchow, N ;

Salzer-Kuntschik, M ;

Treuner, J ;

Veltmann, U ;

Werner, M ;

Winkelmann, W ;

Zoubek, A ;

Kotz, R .

KLINISCHE PADIATRIE, 1999, 211 (04) :260-270

[5] Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].

Bielack, SS ;

Kempf-Bielack, B ;

Delling, G ;

Exner, GU ;

Flege, S ;

Helmke, K ;

Kotz, R ;

Salzer-Kuntschik, M ;

Werner, M ;

Winkelmann, W ;

Zoubek, A ;

Jürgens, H ;

Winkler, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790

[6] Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease [J].

Bollard, CM ;

Savoldo, B ;

Rooney, CM ;

Heslop, HE .

ACTA HAEMATOLOGICA, 2003, 110 (2-3) :139-148

[7]

CAMPANACCI M, 1999, BONE TUMORS, P1418

[8] Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD [J].

Carnevale-Schianca, F ;

Cignetti, A ;

Capaldi, A ;

Vitaggio, K ;

Vallario, A ;

Ricchiardi, A ;

Sperti, E ;

Ferraris, R ;

Gatti, M ;

Grignani, G ;

Rota-Scalabrini, D ;

Geuna, M ;

Fizzotti, M ;

Sangiolo, D ;

Sottile, A ;

De Rosa, G ;

Bucci, AR ;

Lambertenghi-Deliliers, G ;

Benedetti, E ;

Nash, R ;

Aglietta, M .

BLOOD, 2006, 107 (09) :3795-3803

[9] Altered maturation of peripheral blood dendritic cells in patients with breast cancer [J].

Della Bella, S ;

Gennaro, M ;

Vaccari, M ;

Ferraris, C ;

Nicola, S ;

Riva, A ;

Clerici, M ;

Greco, M ;

Villa, ML .

BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1463-1472

[10] High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study [J].

Fagioli, F ;

Aglietta, M ;

Tienghi, A ;

Ferrari, S ;

del Prever, AB ;

Vassallo, E ;

Palmero, A ;

Biasin, E ;

Bacci, G ;

Picci, P ;

Madon, E .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2150-2156

← 1 2 3 4 →